A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry

Biochemical Journal

Volumn 463, Issue 3, 2014, Pages 351-362

  Ma, Yongmin ^a,b   Podinovskaia, Maria ^c   Evans, Patricia J ^d   Emma, Giovanni ^e   Schaible, Ulrich E ^c   Porter, John ^d   Hider, Robert C ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Beads; Flow cytometry; Fluorescence; Iron chelator; Iron overloaded serum; Non transferrin bound iron

Indexed keywords

BIDENTATE HYDROXYPYRANONE; BIDENTATE HYDROXYPYRIDINONE; FERRITIN; FLUORESCENT DYE; HEXADENTATE HYDROXYPYRANONE; HEXADENTATE HYDROXYPYRIDINONE; IRON; IRON CHELATING AGENT; IRON DERIVATIVE; NON TRANSFERRIN BOUND IRON; PLASMA PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG; PROTEIN BINDING; PYRAN DERIVATIVE; PYRIDONE DERIVATIVE; SERUM ALBUMIN;

ARTICLE; AUTOFLUORESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; QUANTITATIVE ANALYSIS; BLOOD; CHEMISTRY; IRON OVERLOAD; METABOLISM; PROCEDURES; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

FERRITINS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; PROTEIN BINDING; PYRANS; PYRIDONES; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERRIN;

EID: 84907812225     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140795     Document Type: Article

References (44)

1. Galanello, R. and Origa, R. (2010) β-Thalassemia. Orphanet J. Rare Dis. 5, 11 CrossRef PubMed
2. Gray, S. G., Crowe, J. and Lawless, M. W. (2009) Hemochromatosis: as a conformational disorder. Int. J. Biochem. Cell Biol. 41, 2094-2097 CrossRef PubMed
3. Gosriwatana, I., Loreal, O., Lu, S., Brissot, P., Porter, J. and Hider, R. C. (1999) Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal. Biochem. 273, 212-220 CrossRef PubMed
4. Goto, T., Ikuta, K., Inamoto, Y., Kamoshita, S., Yokohata, E., Koyama, D., Onodera, K., Seto, A., Watanabe, K., Imahashi, N. et al. (2013) Hyperferritinemia after adult allogeneic hematopoietic cell transplantation: quantification of iron burden by determining non-transferrin-bound iron. Int. J. Hematol. 97, 125-134 CrossRef PubMed
5. Jacobs, E. M., Hendriks, J. C., van Tits, B. L., Evans, P. J., Breuer, W., Liu, D. Y., Jansen, E. H., Jauhiainen, K., Sturm, B., Porter, J. B. et al. (2005) Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal. Biochem. 341, 241-250 CrossRef PubMed
6. Loreal, O., Gosriwatana, I., Guyader, D., Porter, J., Brissot, P. and Hider, R. C. (2000) Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J. Hepatol. 32, 727-733 CrossRef PubMed
7. Porter, J. B., Abeysinghe, R. D., Marshall, L., Hider, R. C. and Singh, S. (1996) Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88, 705-713 PubMed
8. Sasaki, K., Ikuta, K., Tanaka, H., Ohtake, T., Torimoto, Y., Fujiya, M. and Kohgo, Y. (2011) Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination. Mol. Med. Rep. 4, 913-918 PubMed
9. Hershko, C., Graham, G., Bates, G. W. and Rachmilewitz, E. A. (1978) Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 40, 255-263 CrossRef PubMed
10. Hider, R. C. (2002) Nature of nontransferrin-bound iron. Eur. J. Clin. Invest. 32 (Suppl. 1), 50-54 CrossRef PubMed
11. Silva, A. M. and Hider, R. C. (2009) Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim. Biophys. Acta 1794, 1449-1458 CrossRef PubMed
12. Zurlo, M. G., De Stefano, P., Borgna-Pignatti, C., Di Palma, A., Piga, A., Melevendi, C., Di Gregorio, F., Burattini, M. G. and Terzoli, S. (1989) Survival and causes of death in thalassaemia major. Lancet 2, 27-30 CrossRef PubMed
13. 2+channels in iron transport and iron-overload cardiomyopathy. J. Mol. Med. 84, 349-364 CrossRef PubMed
14. Evans, P., Kayyali, R., Hider, R. C., Eccleston, J. and Porter, J. B. (2010) Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl. Res. 156, 55-67 CrossRef PubMed
15. Zanninelli, G., Breuer, W. and Cabantchik, Z. I. (2009) Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. Br. J. Haematol. 147, 744-751 CrossRef PubMed
16. Evans, P. J. and Halliwell, B. (1994) Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Methods Enzymol. 233, 82-92 CrossRef PubMed
17. Nuttall, K. L., Gordon, W. H. and Ash, K. O. (1995) Inductively coupled plasma mass spectrometry for trace element analysis in the clinical laboratory. Ann. Clin. Lab. Sci. 25, 264-271 PubMed
18. Zhang, D., Okada, S., Kawabata, T. and Yasuda, T. (1995) An improved simple colorimetric method for quantitation of non-transferrin-bound iron in serum. Biochem. Mol. Biol. Int. 35, 635-641 PubMed
19. Breuer, W. and Cabantchik, Z. I. (2001) A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal. Biochem. 299, 194-202 CrossRef PubMed
20. Breuer, W., Ermers, M. J., Pootrakul, P., Abramov, A., Hershko, C. and Cabantchik, Z. I. (2001) Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97, 792-798 CrossRef PubMed
21. Cabantchik, Z. I., Breuer, W., Zanninelli, G. and Cianciulli, P. (2005) LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18, 277-287 CrossRef PubMed
22. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. and Cabantchik, Z. I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 104, 1504-1510 CrossRef PubMed
23. Singh, S., Hider, R. C. and Porter, J. B. (1990) A direct method for quantification of non-transferrin-bound iron. Anal. Biochem. 186, 320-323 CrossRef PubMed
24. Makino, T., Nakamura, K. and Takahara, K. (2014) Potential problems in the determination of serum non-transferrin-bound iron using nitrilotriacetic acid and ultrafiltration. Clin. Chim. Acta 429, 12-13 CrossRef PubMed
25. Walter, P. B., Fung, E. B., Killilea, D. W., Jiang, Q., Hudes, M., Madden, J., Porter, J., Evans, P., Vichinsky, E. and Harmatz, P. (2006) Oxidative stress and inflammation in iron-overloaded patients with β-thalassaemia or sickle cell disease. Br. J. Haematol. 135, 254-263 CrossRef PubMed
26. Taher, A., Musallam, K. M., El Rassi, F., Duca, L., Inati, A., Koussa, S. and Cappellini, M. D. (2009) Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br. J. Haematol. 146, 569-572 CrossRef PubMed
27. Piga, A., Longo, F., Duca, L., Roggero, S., Vinciguerra, T., Calabrese, R., Hershko, C. and Cappellini, M. D. (2009) High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol. 84, 29-33 CrossRef PubMed
28. Ma, Y. M. and Hider, R. C. (2009) The selective quantification of iron by hexadentate fluorescent probes. Bioorg. Med. Chem. 17, 8093-8101 CrossRef PubMed
29. Dobbin, P. S., Hider, R. C., Hall, A. D., Taylor, P. D., Sarpong, P., Porter, J. B., Xiao, G. and van der Helm, D. (1993) Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36, 2448-2458 CrossRef PubMed
30. Heinz, U., Hegetschweiler, K., Acklin, P., Faller, B., Lattmann, R. and Schnebli, H. P. (1999) 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew. Chem. Int. Ed. Engl. 38, 2568-2570 CrossRef PubMed
31. Ma, Y., Luo, W., Quinn, P. J., Liu, Z. and Hider, R. C. (2004) Design, synthesis, physicochemical properties, and evaluation of novel iron chelators with fluorescent sensors. J. Med. Chem. 47, 6349-6362 CrossRef PubMed
32. Veprek, P., Hajduch, M., Dzubak, P., Kuklik, R., Polakova, J. and Bezouska, K. (2006) Comblike dendrimers containing Tn antigen modulate natural killing and induce the production of Tn specific antibodies. J. Med. Chem. 49, 6400-6407 CrossRef PubMed
33. Zhou, T., Neubert, H., Liu, D. Y., Liu, Z. D., Ma, Y. M., Kong, X. L., Luo, W., Mark, S. and Hider, R. C. (2006) Iron binding dendrimers: a novel approach for the treatment of haemochromatosis. J. Med. Chem. 49, 4171-4182 CrossRef PubMed
34. 3+. Analyst 138, 96-99 CrossRef PubMed
35. Liu, Z. D. and Hider, R. C. (2002) Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 22, 26-64 CrossRef PubMed
36. Evans, R. W., Rafique, R., Zarea, A., Rapisarda, C., Cammack, R., Evans, P. J., Porter, J. B. and Hider, R. C. (2008) Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 13, 57-74 CrossRef PubMed
37. Breuer, W., Ermers, M. J., Pootrakul, P., Abramov, A., Hershko, C. and Cabantchik, Z. I. (2000) Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy. Transfus. Sci. 23, 241-242 CrossRef PubMed
38. Spasojevic, I., Armstrong, S. K., Brickman, T. J. and Crumbliss, A. L. (1999) Electrochemical behavior of the Fe(III) complexes of the cyclic hydroxamate siderophores alcaligin and desferrioxamine E. Inorg. Chem. 38, 449-454 CrossRef PubMed
39. Turcot, I., Stintzi, A., Xu, J. and Raymond, K. N. (2000) Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates. J. Biol. Inorg. Chem. 5, 634-641 CrossRef PubMed
40. Breuer, W., Hershko, C. and Cabantchik, Z. I. (2000) The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23, 185-192 CrossRef PubMed
41. Dresow, B., Petersen, D., Fischer, R. and Nielsen, P. (2008) Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals 21, 273-276 CrossRef PubMed
42. Lee, D. H., Liu, D. Y., Jacobs, Jr, D. R., Shin, H. R., Song, K., Lee, I. K., Kim, B. and Hider, R. C. (2006) Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 29, 1090-1095 CrossRef PubMed
43. 4-ethenodeoxycytidine excretion in thalassemia patients: markers for lipid peroxidation-induced DNA damage. Free Radic. Biol. Med. 44, 1863-1868 CrossRef PubMed
44. Sharma, M., Saxena, R. and Gohil, N. K. (2009) Fluorescence assay of non-transferrin-bound iron in thalassemic sera using bacterial siderophore. Anal. Biochem. 394, 186-191 CrossRef PubMed